Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Show more
3525 Del Mar Heights Rd., San Diego, CA, 92130, United States
Market Cap
4.786M
52 Wk Range
$1.10 - $8.50
Previous Close
$1.24
Open
$1.24
Volume
62,606
Day Range
$1.19 - $1.24
Enterprise Value
-2.454M
Cash
7.522M
Avg Qtr Burn
-1.329M
Insider Ownership
24.82%
Institutional Own.
6.77%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
XYNGARI™ (formerly DMT310) Details Psoriasis | Failed Discontinued | |
XYNGARI™ (formerly DMT310) Details Moderate-to-severe acne | Failed Discontinued | |
Xyngari + Daxxify Details Primary axillary hyperhidrosis | Failed Discontinued | |
XYNGARI™ (formerly DMT310) Details Papulopustular rosacea | Failed Discontinued |
